Annovis Bio, Inc. financial data

Symbol
ANVS on NYSE
Location
Malvern, PA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 13 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 19% % -93%
Return On Equity -159% % 82%
Return On Assets -133% % 44%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28,355,262 shares 46%
Common Stock, Shares, Outstanding 27,199,139 shares 92%
Entity Public Float $36,076,450 USD -30%
Common Stock, Value, Issued $2,719 USD 92%
Weighted Average Number of Shares Outstanding, Basic 20,551,997 shares 69%
Weighted Average Number of Shares Outstanding, Diluted 20,551,997 shares 68%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $25,215,607 USD 26%
General and Administrative Expense $4,479,651 USD -33%
Operating Income (Loss) $29,695,258 USD -11%
Nonoperating Income (Expense) $841,061 USD -60%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $40,939,110 USD 1.9%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $28,854,197 USD -17%
Earnings Per Share, Basic -1.4 USD/shares 31%
Earnings Per Share, Diluted -1.4 USD/shares 39%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $19,532,338 USD 85%
Assets $21,081,625 USD 51%
Accounts Payable, Current $2,590,516 USD 12%
Employee-related Liabilities, Current $426,202 USD 17%
Liabilities, Current $3,635,375 USD -6.3%
Liabilities $4,230,375 USD -8.4%
Retained Earnings (Accumulated Deficit) $163,703,659 USD -21%
Stockholders' Equity Attributable to Parent $16,851,250 USD 81%
Liabilities and Equity $21,081,625 USD 51%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,099,164 USD -15%
Net Cash Provided by (Used in) Financing Activities $19,783,423 USD 348%
Common Stock, Shares Authorized 70,000,000 shares 0%
Common Stock, Shares, Issued 27,199,139 shares 92%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $11,684,259 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19,532,338 USD 85%
Deferred Tax Assets, Valuation Allowance $45,809,555 USD 23%
Deferred Tax Assets, Gross $45,809,555 USD 23%
Deferred Tax Assets, Operating Loss Carryforwards $18,213,829 USD 34%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2,000,000 shares 0%
Additional Paid in Capital $180,552,190 USD 25%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $444,647 USD 13%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%